This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.&nbsp; The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/corevalve-us-pivotal-trial-2-year-results-of-the-self-expanding-valve-on-inoperable-patients/" title="Read more" >...</a>

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P &lt;0.0001). By dividing patients by STS<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-5-year-results-of-a-balloon-expandable-valve-on-inoperable-patients/" title="Read more" >...</a>

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE &gt; 18.5<a href="https://solaci.org/en/2015/06/24/uk-tavi-registry-long-term-results-of-tavi-in-the-uk/" title="Read more" >...</a>

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with severe aortic stenosis who received TAVI at 14 sites in Asia (Edwards Sapiens: 140 patients; Medtronic Core Valve: 113 patients). The success rate was<a href="https://solaci.org/en/2015/06/24/clinical-results-of-tavi-in-asia/" title="Read more" >...</a>

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received the device and were followed during 30 days. Mortality from all causes was 1.7% and the incidence of stroke was 8.6%, with half<a href="https://solaci.org/en/2015/06/24/reprise-ii-results-obtained-with-the-new-valve-according-to-varc-criteria/" title="Read more" >...</a>

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis and high surgical risk. The device is designed to reduce post-implant aortic regurgitation; it has a low profile and high navigability and requires no post-dilatation or rapid pacing. The study included<a href="https://solaci.org/en/2015/06/24/discover-new-low-profile-valve-with-little-post-implant-regurgitation/" title="Read more" >...</a>

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days was 85.1% with a cardiovascular death rate of 4.8%. No strokes were observed during this period. Average gradient reduction was highly significant, (40.4 to 8.1 mmHg, p &lt;0.001), as well as<a href="https://solaci.org/en/2015/06/24/jupiter-transapical-tavi-device/" title="Read more" >...</a>